## Tanya N Turan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/191178/publications.pdf

Version: 2024-02-01

110 papers 47,036 citations

66234 42 h-index 103 g-index

110 all docs

110 docs citations

110 times ranked

56111 citing authors

#	Article	IF	CITATIONS
1	Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach. Journal of Hypertension, 2022, 40, 462-469.	0.3	8
2	Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurology, The, 2022, 21, 355-368.	4.9	89
3	Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory. Neurology, 2022, 98, 486-498.	1.5	46
4	Long-Term Secondary Prevention: Management of Blood Pressure After a Transient Ischemic Attack or Stroke. Stroke, 2022, 53, 1085-1103.	1.0	6
5	Hypertensive Disorders of Pregnancy With and Without Prepregnancy Hypertension Are Associated With Incident Maternal Kidney Disease Subsequent to Delivery. Hypertension, 2022, 79, 844-854.	1.3	3
6	White matter hyperintensity progression is associated with incident probable dementia or mild cognitive impairment. Stroke and Vascular Neurology, 2022, 7, 364-366.	1.5	6
7	Implementation of an International Vessel Wall MR Plaque Imaging Research Network: Experience with the ChAMPION Study. Clinical and Translational Neuroscience, 2022, 6, 16.	0.4	O
8	Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology, 2021, 96, e2824-e2838.	1.5	95
9	Maternal Coronary Heart Disease, Stroke, and Mortality Within 1, 3, and 5 Years of Delivery Among Women With Hypertensive Disorders of Pregnancy and Preâ€Pregnancy Hypertension. Journal of the American Heart Association, 2021, 10, e018155.	1.6	30
10	High-resolution vessel wall imaging after mechanical thrombectomy. Neuroradiology Journal, 2021, 34, 593-599.	0.6	9
11	White Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105764.	0.7	5
12	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke, 2021, 52, e364-e467.	1.0	1,123
13	Asymptomatic Intracranial Atherosclerotic Stenosis. Journal of the American College of Cardiology, 2021, 78, 572-574.	1.2	O
14	Non-Adherence to Antihypertensive Guidelines in Patients with Asymptomatic Carotid Stenosis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105918.	0.7	5
15	Incident Heart Failure Within the First and Fifth Year after Delivery Among Women With Hypertensive Disorders of Pregnancy and Prepregnancy Hypertension in a Diverse Population. Journal of the American Heart Association, 2021, 10, e021616.	1.6	15
16	Cilostazol for Secondary Stroke Prevention. Stroke, 2021, 52, e635-e645.	1.0	17
17	Submaximal Angioplasty for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis of Peri-Procedural and Long-Term Risk. Neurosurgery, 2020, 86, 755-762.	0.6	24
18	Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105254.	0.7	13

#	Article	IF	CITATIONS
19	Mitigating the effects of COVID-19 pandemic on controlling vascular risk factors among participants in a carotid stenosis trial. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105362.	0.7	3
20	Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. Stroke, 2020, 51, 2960-2971.	1.0	19
21	The CREST-2 experience with the evolving challenges of COVID-19. Neurology, 2020, 95, 29-36.	1.5	10
22	Optimized Hemodynamic Assessment to Predict Stroke Risk in Vertebrobasilar Disease: Analysis From the VERiTAS Study. Journal of the American Heart Association, 2020, 9, e016406.	1.6	9
23	Relationship Between Vascular Risk Factors and Location of Intracranial Atherosclerosis in the SAMMPRIS Trial. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104713.	0.7	7
24	Secondary Stroke Prevention and Management for the Neuro-Ophthalmologist. Journal of Neuro-Ophthalmology, 2020, 40, 463-471.	0.4	0
25	Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104371.	0.7	2
26	Impact of Baseline Features and Risk Factor Control on Cognitive Function in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Cerebrovascular Diseases, 2019, 47, 24-31.	0.8	6
27	Type and Duration of Exercise in the SAMMPRIS Trial. Neurologist, 2019, 24, 10-12.	0.4	6
28	Hemodynamic Markers in the Anterior Circulation as Predictors of Recurrent Stroke in Patients With Intracranial Stenosis. Stroke, 2019, 50, 143-147.	1.0	66
29	Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 801-805.	0.7	16
30	Development of a high resolution MRI intracranial atherosclerosis imaging phantom. Journal of NeuroInterventional Surgery, 2018, 10, 143-149.	2.0	13
31	Characterization of Recurrent Strokes With and Without Patent Foramen Ovale Closure. Journal of the American College of Cardiology, 2018, 72, 2542-2544.	1.2	1
32	Phentermine associated recurrent intracerebral hemorrhage. Journal of the Neurological Sciences, 2018, 393, 135-137.	0.3	5
33	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 2018, 72, e53-e90.	1.3	629
34	High-Resolution Magnetic Resonance Imaging Evidence for Intracranial Vessel Wall Inflammation Following Endovascular Thrombectomy. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, e96-e98.	0.7	8
35	Postprandial Clearance of Oxidized Low-Density Lipoprotein in Patients with Stroke Due to Atherosclerosis. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 488-493.	0.7	7
36	Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. International Journal of Stroke, 2017, 12, 770-778.	2.9	162

#	Article	IF	CITATIONS
37	Nonprocedural Symptomatic Infarction and In-Stent Restenosis After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial (Stenting and Aggressive Medical Management for the Prevention of) Tj ETQq1 1	. 0 <b>178</b> 4314	4 rgBT /Over
38	Vertebrobasilar atherosclerotic disease: is it time to revisit angioplasty?. Journal of NeuroInterventional Surgery, 2017, 9, 1033-1034.	2.0	6
39	Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology, 2017, 88, 379-385.	1.5	125
40	Large Artery Atherosclerosis: Extracranial and Intracranial. Seminars in Neurology, 2017, 37, 307-315.	0.5	9
41	Cerebral Venous Sinus Thrombosis Due to Low–molecular-weight Heparin-induced Thrombocytopenia. Neurologist, 2017, 22, 241-244.	0.4	14
42	Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 62.	0.4	34
43	Light-induced Hemiplegia, an Atypical Case of Retinal Steal Syndrome. Neurologist, 2017, 22, 57-60.	0.4	0
44	Higher Stroke Risk with Lower Blood Pressure in Hemodynamic Vertebrobasilar Disease: Analysis from the VERiTAS Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 403-410.	0.7	30
45	Is There Benefit from Stenting on Cognitive Function in Intracranial Atherosclerosis?. Cerebrovascular Diseases, 2017, 43, 31-35.	0.8	12
46	Impact of the New American Heart Association/American Stroke Association Definition of Stroke on the Results of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 108-115.	0.7	7
47	Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, e38-360.	1.6	5,447
48	Factors Associated With Recurrent Ischemic Stroke in the Medical Group of the SAMMPRIS Trial. JAMA Neurology, 2016, 73, 308.	4.5	54
49	Executive Summary: Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, 447-454.	1.6	2,093
50	Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial Arterial Stenosis. JAMA Neurology, 2016, 73, 36.	4.5	54
51	Vessel and Vessel Wall Imaging. Frontiers of Neurology and Neuroscience, 2016, 40, 109-123.	3.0	14
52	Secondary Prevention After Symptomatic Large Artery Intracranial Disease., 2016,, 161-167.		0
53	Characterization of intracranial atherosclerotic stenosis using highâ€resolution <scp>MRI</scp> study – rationale and design. Brain and Behavior, 2015, 5, e00397.	1.0	27
54	Enrollment volume effect on risk factor control and outcomes in the SAMMPRIS trial. Neurology, 2015, 85, 2090-2097.	1.5	4

#	Article	IF	Citations
55	Executive Summary: Heart Disease and Stroke Statistics—2015 Update. Circulation, 2015, 131, 434-441.	1.6	509
56	Outcome in Patients Previously on Antithrombotic Therapy in the SAMMPRIS Trial. Stroke, 2015, 46, 775-779.	1.0	21
57	Heart Disease and Stroke Statistics—2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
58	Practical Approach to Management of Intracranial Atherosclerosis. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 369.	0.4	1
59	Do Patient Characteristics Explain the Differences in Outcome Between Medically Treated Patients in SAMMPRIS and WASID?. Stroke, 2015, 46, 2562-2567.	1.0	33
60	Hemodynamic Features of Symptomatic Vertebrobasilar Disease. Stroke, 2015, 46, 1850-1856.	1.0	45
61	Yet again no benefit of stenting over medical therapy. Lancet Neurology, The, 2015, 14, 565-566.	4.9	4
62	Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?. Stroke, 2015, 46, 3282-3284.	1.0	35
63	Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention. Circulation, 2015, 132, 1157-1213.	1.6	446
64	Racial Differences in Poststroke Rehabilitation Utilization and Functional Outcomes. Archives of Physical Medicine and Rehabilitation, 2015, 96, 84-90.e1.	0.5	40
65	Comparison of endovascular treatment approaches for acute ischemic stroke: cost effectiveness, technical success, and clinical outcomes. Journal of NeuroInterventional Surgery, 2015, 7, 666-670.	2.0	125
66	Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
67	Intracranial Stenosis: Impact of Randomized Trials on Treatment Preferences of US Neurologists and Neurointerventionists. Cerebrovascular Diseases, 2014, 37, 203-211.	0.8	37
68	Infarct Patterns, Collaterals and Likely Causative Mechanisms of Stroke in Symptomatic Intracranial Atherosclerosis. Cerebrovascular Diseases, 2014, 37, 417-422.	0.8	73
69	Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet, The, 2014, 383, 333-341.	<b>6.</b> 3	672
70	Executive Summary: Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, 399-410.	1.6	1,295
71	Intracranial atherosclerosis: Correlation between in-vivo 3T high resolution MRI and pathology. Atherosclerosis, 2014, 237, 460-463.	0.4	71
72	Abstract 78: Risk Factors Associated with Failure of Aggressive Medical Therapy in the SAMMPRIS Trial. Stroke, 2014, 45, .	1.0	2

#	Article	IF	Citations
73	The Challenge of Stroke Prevention with Intracranial Arterial Stenosis. Current Cardiology Reports, 2013, 15, 422.	1.3	3
74	Executive Summary: Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, 143-152.	1.6	1,179
75	Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, e6-e245.	1.6	4,387
76	Highâ€resolution <scp>MRI</scp> of basilar atherosclerosis: threeâ€dimensional acquisition and <scp>FLAIR</scp> sequences. Brain and Behavior, 2013, 3, 1-3.	1.0	17
77	Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurology, The, 2013, 12, 1106-1114.	4.9	353
78	An Updated Definition of Stroke for the 21st Century. Stroke, 2013, 44, 2064-2089.	1.0	2,371
79	Intracranial Stenting: SAMMPRIS. Stroke, 2013, 44, S41-S44.	1.0	8
80	High-Resolution Magnetic Resonance Imaging. Stroke, 2013, 44, 287-292.	1.0	124
81	Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. Journal of NeuroInterventional Surgery, 2013, 5, 528-533.	2.0	58
82	Utilization of CT perfusion patient selection for mechanical thrombectomy irrespective of time: a comparison of functional outcomes and complications. Journal of NeuroInterventional Surgery, 2013, 5, 518-522.	2.0	25
83	Mechanisms of Stroke After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial. Neurosurgery, 2013, 72, 777-795.	0.6	128
84	Rationale, Design, and Implementation of Aggressive Risk Factor Management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, e51-60.	0.9	45
85	CT perfusion-guided patient selection for endovascular treatment of acute ischemic stroke is safe and effective. Journal of NeuroInterventional Surgery, 2012, 4, 261-265.	2.0	41
86	Executive Summary: Heart Disease and Stroke Statistics—2012 Update. Circulation, 2012, 125, 188-197.	1.6	1,172
87	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. Stroke, 2012, 43, 3442-3453.	1.0	248
88	Response to Critique of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial by Abou-Chebl and Steinmetz. Stroke, 2012, 43, 2806-2809.	1.0	6
89	Detailed Analysis of Periprocedural Strokes in Patients Undergoing Intracranial Stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke, 2012, 43, 2682-2688.	1.0	168
90	REACH MUSC: A Telemedicine Facilitated Network for Stroke: Initial Operational Experience. Frontiers in Neurology, 2012, 3, 33.	1.1	21

#	Article	IF	CITATIONS
91	Heart Disease and Stroke Statistics—2012 Update. Circulation, 2012, 125, e2-e220.	1.6	4,096
92	Abstract 141: Impact of an Aggressive Medical Management Protocol on Early Risk Factor Measures in the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) Trial. Stroke, 2012, 43, .	1.0	2
93	Abstract 208: Detailed Analysis of the 30-day Outcomes in the Stenting Arm of the SAMMPRIS Trial. Stroke, 2012, 43, .	1.0	1
94	MUSC's comprehensive stroke program: changing what's possible in stroke care across South Carolina. The Journal of the South Carolina Medical Association, 2012, 108, 128-31.	0.0	2
95	Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis. New England Journal of Medicine, 2011, 365, 993-1003.	13.9	1,588
96	Heart Disease and Stroke Statisticsâ€"2011 Update. Circulation, 2011, 123, e18-e209.	1.6	4,379
97	Design of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 357-368.	0.7	107
98	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke, 2011, 42, 227-276.	1.0	1,433
99	Intraplaque Hemorrhage in Symptomatic Intracranial Atherosclerotic Disease. , 2011, 21, e159-e161.		66
100	Collaterals dramatically alter stroke risk in intracranial atherosclerosis. Annals of Neurology, 2011, 69, 963-974.	2.8	258
101	Intracerebral Hemorrhage. Neurologist, 2011, 17, 292-296.	0.4	9
102	10 Questions About Intracranial Atherosclerotic Stenosis. Neurologist, 2010, 16, 400-405.	0.4	0
103	Risk Factors Associated With Severity and Location of Intracranial Arterial Stenosis. Stroke, 2010, 41, 1636-1640.	1.0	104
104	Failure of Antithrombotic Therapy and Risk of Stroke in Patients With Symptomatic Intracranial Stenosis. Stroke, 2009, 40, 505-509.	1.0	56
105	Treatment of Atherosclerotic Intracranial Arterial Stenosis. Stroke, 2009, 40, 2257-2261.	1.0	44
106	Treatment of intracranial atherosclerotic stenosis. Reviews in Neurological Diseases, 2008, 5, 117-24.	0.3	6
107	Relationship Between Blood Pressure and Stroke Recurrence in Patients With Intracranial Arterial Stenosis. Circulation, 2007, 115, 2969-2975.	1.6	149
108	Clinical Characteristics of Patients With Early Hospital Arrival After Stroke Symptom Onset. Journal of Stroke and Cerebrovascular Diseases, 2005, 14, 272-277.	0.7	20

## Tanya N Turan

#	Article	IF	CITATIONS
109	Posttraumatic Cerebrospinal Fluid Hypertension and Hypotension. Archives of Neurology, 2004, 61, 1124-5.	4.9	2
110	Stroke in pregnancy. Neurologic Clinics, 2004, 22, 821-840.	0.8	21